


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims

What is claimed is:

1. (Currently Amended) A method of treating Use of a compound of formula (I) or a 3-enol C_{1 to 4} alkanooate ester thereof in the manufacture of a medicament for the treatment of an angiotensin II related disease in humans and animals a patient, comprising administering to a patient in need thereof an effective amount of a compound of formula (I):





or a 3-enol C_{1 to 4} alkanooate ester thereof,

wherein R₁, R₂, R₅, R₆ are the same or different and each is hydrogen or C_{1 to 4} alkyl;

R₃ is hydrogen, C_{1 to 4} alkyl, C_{2 to 4} alkenyl or C_{2 to 4} alkynyl;

R₄ is hydroxyl, C_{1 to 4} alkanoyloxy, or a group of formula (II) or (III)



wherein R₇ is (CH₂)_n, where n is an integer of from 0 to 4, R₈ is hydrogen, C_{1 to 4} alkyl, hydroxy or NH₂ and R₉ and R₁₀ are the same or different and each is hydrogen or C_{1 to 4} alkyl; or R₃ and R₄ together are oxo, ethylenedioxy or propylenedioxy.

2. (Currently Amended) A method Use according to claim 1, wherein in formula (I) R₁ is hydrogen or methyl; ~~and/or~~ R₂ is hydrogen or methyl; ~~and/or~~ R₄ is hydroxy or R₃ and R₄ together are oxo; and ~~and/or~~ R₅ and R₆ are methyl.

3. (Currently Amended) A method Use according to claim 1, wherein the compound of formula (I) is trilostane, ketotrilostane or epostane.

4. (Currently Amended) A method Use according to claim 1 ~~any one of claims 1 to 3~~, wherein the angiotensin II related disease is a cardiovascular disease.

5. (Currently Amended) A method Use according to claim 4 ~~any one of the previous claims~~, wherein the ~~angiotensin II related~~ cardiovascular disease is congestive heart failure, post myocardial infarction, cardiomyopathy, diabetes, renal failure, metabolic syndrome (Syndrome X) or arrhythmia.

6. (Currently Amended) A method Use according to claim 4, wherein the cardiovascular disease is post myocardial infarction.

7. (Currently Amended) A method Use according to claim 1 ~~any one of the preceding claims~~, wherein the compound of formula (I) ~~medicament~~ is administered in an amount of from 0.5 to 4 mg/kg/day.

8. (Currently Amended) A method Use according to claim 1 ~~any one of claims 1 to 3~~, wherein the angiotensin II related disease is a proliferative disease.

9. (Currently Amended) A method Use according to claim 8, wherein the proliferative disease is peripheral arterial disease, cerebro vascular disease, cardiofibrosis, cardiac myopathy, diabetic retinopathy, diabetic gangrene, diabetic nephropathy, scleroderma, aneurism, asthma or atheroma.

10. (Currently Amended) A method Use according to ~~claim 8~~ or claim 9, wherein the proliferative disease is cardiofibrosis.

11. (Currently Amended) A method Use according to claim 8 ~~any one of claims 8 to 10,~~ wherein the proliferative disease is cardiofibrosis following infarction.
12. (Currently Amended) A method Use according to claim 8 ~~any one of the preceding claims,~~ wherein the compound of formula (I) medicament is administered in an amount of from 0.5 to 4 mg/kg/day.
13. (Currently Amended) A method Use according to claim 1 ~~any of the preceding claims~~ wherein the compound of formula (I) medicament ~~comprises the compound of formula (I) or a 3-enol C_{1 to 4} alkanooate ester thereof as defined in claims 1 to 3,~~ is in particulate form.
14. (Currently Amended) A method Use according to claim 13 wherein the particles of the particulate form compound have a mean equivalent sphere volume diameter of up to 12 µm and 95% or more of the particles have a particle size of up to 50 µm.
15. (Currently Amended) A method Use according to ~~claim 13 or~~ claim 14 wherein the particles have a mean equivalent sphere volume diameter of from 5 to 12 µm.
16. (Currently Amended) A method Use according to ~~any one of claims 13 to 15~~ claim 13 wherein the particles have a mean equivalent sphere volume diameter of up to 5 µm.
17. (Currently Amended) A method Use according to ~~any one of claims 13 to 16~~ claim 13 wherein the specific surface area of the particulate compound is 2 m²g⁻¹ or higher or 5 m²g⁻¹ or higher.
18. (Currently Amended) A method Use according to ~~any one of the preceding claims~~ claim 1 wherein the compound of formula (I) medicament is administered orally either as a tablet, a capsule or a liquid dispersion.
19. (Currently Amended) A method Use according to claim 1 ~~of any one of the preceding claims wherein the medicament comprises~~ comprising administering a unit dosage of from 0.25 mg to 1000 mg of a compound of formula (I) or a 3-enol C_{1 to 4} alkanooate ester thereof as ~~defined in claims 1 to 3.~~

20. (Currently Amended) A method Use according to claim 19 wherein the unit dosage is from 0.5 mg to 25 mg.
21. (Currently Amended) A method Use according to claim 19, wherein the unit dosage is from 25 to 1000 mg.
22. (Currently Amended) A method Use according to claim 1 ~~any one of the preceding claims~~ wherein the treatment of an angiotensin II related cardiovascular disease with a compound of formula (I) or a 3-enol C_{1 to 4} alkanoate ester thereof is carried out in combination with a further treatment of one or more of:
- an Angiotensin Converting Enzyme (ACE) inhibitor;
 - an angiotensin II receptor blocker;
 - an aldosterone inhibitor or agent used for lowering aldosterone levels or blocking the effects of aldosterone in the body; or
 - a steroidogenesis inhibitor.
23. (Currently Amended) A method Use according to claim 22 wherein the aldosterone inhibitor or agent used for lowering aldosterone levels is an ACE inhibitor.
24. (Currently Amended) A method Use according to claim ~~22 or~~ 23 wherein the ACE inhibitor is Captopril, Enalapril or Lisinopril.
25. (Currently Amended) A method Use according to claim 22 wherein the aldosterone inhibitor or agent for blocking the effects of aldosterone is Spironolactone or Eplerenone.
26. (Currently Amended) A method Use according to claim 22 wherein the angiotensin II receptor blocker is Losartan or Candasartan.
27. (Currently Amended) A method Use according to claim 22 wherein the steroidogenesis inhibitor is aminoglutethimide or metyrapone.
28. (Currently Amended) A ~~medicament~~ pharmaceutical composition comprising:

(a) a compound of formula (I) or a 3-enol C_{1 to 4} alkanoate ester thereof as defined in ~~claims 1 to 3 and 13 to 17~~ claim 1; and

(b) one or more of:

- an ACE inhibitor;
- an angiotensin II receptor blocker;
- an inhibitor or agent used for lowering aldosterone levels or blocking the effects of aldosterone; or
- a steroidogenesis inhibitor

~~as defined in any one of claims 22 to 27, for simultaneous, separate or sequential use in the treatment of an angiotensin II related disease as defined in any one of claims claim 4 to 6 or 8 to 11.~~

29. (Canceled)

30. (Currently Amended) A method of treating an angiotensin II related disease by administering to a patient having said disease an amount of a compound of formula (I) or a 3-enol C_{1to4} alkanoate ester thereof as defined in ~~any of claims 1 to 3 or 13 to 17~~ claim 1 and an amount of one or more of:

- an ACE inhibitor;
- an angiotensin II receptor blocker;
- an aldosterone inhibitor or agent for lowering aldosterone levels or blocking the effects of aldosterone; or
- a steroidogenesis inhibitor

effective to treat said disease.

31. (Currently Amended) A method according to claim ~~29 or~~ 30 wherein the angiotensin II related ~~is a disease as defined according to claim 4 to 6 or 8 to 11~~ disease is a cardiovascular disease or a proliferative disease.